Trial Profile
A Study to Evaluate the Efficacy of CJM-112 in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Transitioning from Natalizumab
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 17 Feb 2016
Price :
$35
*
At a glance
- Drugs CJM 112 (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms MABINGO
- 17 Feb 2016 New trial record